Happy Holidays and New year from the EMDB! Please be advised that the EMDB team will be operating at reduced capacity between December 15th - January 12th. With this in mind we would ask that you be prepared for longer reply times through both our helpdesk system and the OneDep deposition system. well done on a productive 2025, wishing you all the best and we will see you in 2026!

EMD-47403

Single-particle
2.56 Å
EMD-47403
3D View Gallery
Deposition: 21/10/2024
Map released: 30/10/2024
Last modified: 25/06/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-47403
Download
3D volume (map.gz) Experimental metadata (xml) Experimental Metadata (cif.gz)
Map-only Validation report (pdf.gz) Map-only Validation report (cif.gz) Map-only Validation report (xml.gz)
EMICSS annotations (xml)

Structure of RyR1 in the primed state in the presence of allopurinol, focused refinement

EMD-47403

Single-particle
2.56 Å
EMD-47403
3D View Gallery
Deposition: 21/10/2024
Map released: 30/10/2024
Last modified: 25/06/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Oryctolagus cuniculus
Sample: Complex of RyR1 and Calstabin-1

Deposition Authors: Miotto MC , Marks AR
Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders.
Miotto MC , Luna-Figueroa E, Tchagou C, Bahlouli L, Reiken S , Dridi H, Liu Y , Weninger G , Marks AR
(2025) PNAS , 122 , e2422082122 - e2422082122
PUBMED: 40512792
DOI: doi:10.1073/pnas.2422082122
ISSN: 1091-6490
ASTM: PNASA6
Grant Support: